Log In
BCIQ
Print this Print this
 

Buphenyl, sodium phenylbutyrate

  Manage Alerts
Collapse Summary General Information
Company Horizon Pharma plc
DescriptionTablet formulation of sodium phenylbutyrate
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationUrea cycle disorder (UCD)
Indication DetailsAdjunctive therapy in the chronic management of urea cycle disorders (UCD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,100.0M

$1,100.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/07/2015

$1,100.0M

$1,100.0M

0

Get a free BioCentury trial today